Recursion (NASDAQ: RXRX) has appointed Dr. Najat Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson, as its Chief R&D Officer and Chief Commercial Officer. Dr. Khan will also join Recursion’s board of directors.
Dr. Khan's appointment is significant as she brings a unique blend of leadership in biological, chemical, and medical sciences, data science, and business. Her expertise spans the pharmaceutical and healthcare industry, with a focus on driving substantial patient and business value.
Recursion is positioning itself as a pioneer in the burgeoning techbio sector, aiming to decode biology and chemistry to radically improve lives. The company's approach involves uniting technology, biology, chemistry, and patient-centric data to advance the future of medicine. Recursion leverages sophisticated machine-learning algorithms to distill a collection of trillions of searchable relationships across biology and chemistry, unconstrained by human bias. This is facilitated by commanding massive experimental scale, conducting up to millions of wet lab experiments weekly, and owning and operating one of the most powerful supercomputers in the world.
Dr. Khan's mission aligns with Recursion's goal to revolutionize the way transformative medicines are discovered, developed, and delivered for patients. Her appointment is expected to drive Recursion's portfolio pipeline and create commercial strategies as the company continues to industrialize the creation of high-impact medicines.
As a board member of the Alliance for Artificial Intelligence in Healthcare and a steering committee member of the White House’s Moonshot CancerX program, Dr. Khan's industry insight and strategic vision are anticipated to be highly valuable as Recursion enters the era of AI-enabled drug discovery and development.
Recursion is headquartered in Salt Lake City and is a founding member of BioHive, the Utah life sciences industry collective. The company also has offices in Toronto, Montreal, and the San Francisco Bay Area.
This move reflects Recursion's commitment to leveraging top talent and expertise to drive its mission forward in the rapidly evolving pharmaceutical and healthcare industry. Following these announcements, the company's shares moved -2.5%, and are now trading at a price of $7.59. If you want to know more, read the company's complete 8-K report here.
